BPC-157 — Published Research

BPC-157 has been investigated for its interactions with the nitric oxide (NO) system across multiple experimental models. Studies in rats demonstrated that BPC-157 counteracts the effects of both NO synthase inhibitors (L-NAME) and NO synthase substrates (L-arginine) on gastrointestinal motility and vascular tone. This bidirectional modulation suggests the peptide interacts with the NO system at a regulatory rather than direct enzymatic level, potentially involving eNOS and iNOS expression changes.

Sikiric P et al. “Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications.” Curr Neuropharmacol. 2016. PubMed

An in vitro study using rat Achilles tendon fibroblasts examined the effects of BPC-157 on growth hormone receptor (GHR) expression. At concentrations from 1 to 100 ng/mL, the peptide upregulated GHR mRNA expression in a dose-dependent manner. Western blot analysis confirmed increased GHR protein levels. The study also observed increased phosphorylation of JAK2 and STAT5 downstream signaling molecules, suggesting BPC-157 may modulate the GH/IGF-1 axis at the receptor level in connective tissue cells.

Chang CH et al. “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.” Molecules. 2014. PubMed

BPC-157 has been studied extensively in gastrointestinal models including ethanol-induced gastric lesions, NSAID-induced intestinal damage, and inflammatory bowel disease models in rats. The peptide demonstrated cytoprotective activity across multiple GI regions . Mechanistic investigations suggest involvement of prostaglandin and dopamine system modulation, as well as effects on VEGF-mediated angiogenesis in damaged mucosal tissue.

Sikiric P et al. “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease.” Ann N Y Acad Sci. 2006. PubMed

A comprehensive review examined BPC-157 research across tendon, ligament, bone, and muscle injury models. Studies in rat Achilles tendon transection models showed accelerated collagen fiber organization. In muscle crush injury models, BPC-157 administration was associated with altered expression of early growth response gene 1 (EGR-1) and its downstream targets including collagen type I and VEGF. The peptide has been studied across these models.

Vukojevic J et al. “Pentadecapeptide BPC 157 and the central nervous system.” Neural Regen Res. 2022. PMC